HK Stock Market Move | Oil stocks are under pressure again, with international oil prices dropping significantly. The market still faces multiple uncertainties.
Oil stocks are under pressure again. As of the time of writing, CNOOC (00857) fell by 3% to 5.49 Hong Kong dollars; CNOOC (00883) fell by 2.54% to 16.84 Hong Kong dollars; CNOOC Oilfield Services (02883) fell by 2.31% to 7.18 Hong Kong dollars.
Oil stocks are under pressure again. As of the end of the reporting period, China Petroleum (00857) fell by 3% to HK$5.49; CNOOC (00883) fell by 2.54% to HK$16.84; China Oilfield Services (02883) fell by 2.31% to HK$7.18; Sinopec (00386) fell by 2.09% to HK$4.22.
On the news front, oil prices fell sharply last night due to the drag of the US dollar. WTI December crude oil futures closed down $2.30, a drop of more than 3.32%, to $68.04 per barrel. Brent January crude oil futures closed down $2.04, a drop of more than 2.76%, to $73.87 per barrel. GF Futures believes that supply pressure easing, weak demand, a stronger US dollar, and geopolitical uncertainties coexist. In the short term, oil prices face downward pressure, but the space is relatively limited, and there is a high probability of continued wide fluctuations in oil prices.
Related Articles
.png)
HK Stock Market Move | TEXWINCA HOLD (00321) rose more than 7% against the market, with Single's Day sales reaching a new high, and the GMV of its e-commerce business increasing by 46% in the first half of the year.

Ze Jing Pharmaceuticals (688266.SH): Injection ZG006 in combination with PD-1/PD-L1 immune checkpoint inhibitors and chemotherapy (Etoposide/Cisplatin) has obtained approval for clinical trials of drug.

Zhongjin: The expectation of power shortage in North America is expected to continue, which is likely to drive the release of demand in areas such as machinery and equipment in our country.
HK Stock Market Move | TEXWINCA HOLD (00321) rose more than 7% against the market, with Single's Day sales reaching a new high, and the GMV of its e-commerce business increasing by 46% in the first half of the year.
.png)
Ze Jing Pharmaceuticals (688266.SH): Injection ZG006 in combination with PD-1/PD-L1 immune checkpoint inhibitors and chemotherapy (Etoposide/Cisplatin) has obtained approval for clinical trials of drug.

Zhongjin: The expectation of power shortage in North America is expected to continue, which is likely to drive the release of demand in areas such as machinery and equipment in our country.

RECOMMEND

U.S. equities face “key defense lines,” testing bullish conviction; a break would confirm a downtrend into “early next year”
17/11/2025

Year-to-date Hong Kong share buybacks surpass HK$140 billion, with technology and financials leading activity
17/11/2025

Bitcoin’s year-to-date 30% rally “fully erased,” market slips into a bear phase
17/11/2025


